Hirsutism means the growth of excessive male-pattern hair in women after puberty. It affects facial and body areas dependent on androgens, namely mustache and beard, pubic hair, buttocks, and thighs. It is a frequent reason for dermatological consultation.
The causes of hirsutism are variable. The condition may be of ovarian or adrenal origin, tumoral or not. The following are some examples.
Hirsutism is most often due to hyperproduction of androgens, of ovarian or adrenal origin. Hyperandrogenism of tumor origin, which is very severe, must be distinguished from non-tumor hyperandrogenism, which is often minimal or moderate.
Polycystic Ovary Syndrome (PCOS)
It represents the most common cause of hirsutism and causes about 75% of all cases. It affects 5% to 10% of women during their period of genital activity and 20% to 25% of adolescent girls. It is a heterogeneous and complex syndrome of unknown etiology characterized by the end of follicular maturation with an accumulation of small follicles under the cortex and a hyperplasia of the ovarian stroma.
Hirsutism appears at puberty, accompanied by disturbances of the menstrual cycle, weight gain, dyslipidemia, insulin resistance, acne, and acanthosis nigricans. The patient reports spaniomenorrhea (prolongation of the cycle beyond 35 days), oligomenorrhea (less abundant menstruation), and infertility. The ovaries can be enlarged. Hypothyroidism or liver disease may be present.
Hyperandrogenism due to ovarian or adrenal tumors is rare. It is responsible for only 0.2% of all cases of hirsutism. These androgen-secreting tumors are autonomous, and therefore, do not depend on the hypothalamic-pituitary axis. Approximatively 50% of them are malignant, and in these cases, the plasma androgen levels are very high. They are also responsible for rapid-onset of virilization, hirsutism and a pelvic or abdominal mass.
Non-classical Congenital Adrenal Hyperplasia (NCAH)
This is a common autosomal recessive disorder, caused by a partial 21-hydroxylase deficiency, and represents the most common adrenal etiology of hyperandrogenism. Its prevalence varies greatly according to the ethnicity of the patients. So it is more common in the Ashkenazi Jewish population (3.7%) and the Central European population (2%) and rare in Caucasians (0.1%). Like PCOS, NCAH can be expressed after the puberty by hirsutism, oligomenorrhea, acne, infertility, alopecia, and primary amenorrhoea.
Many drugs can cause hirsutism: androgens, glucocorticosteroids, progestins, estrogen antagonists (clomiphene, tamoxifen), minoxidil, cyclosporine, danazol, diazoxide, phenytoin, D-penicillamine, and interferon.
It is important to know that hypertrichosis could also be caused by certain medications such as acetazolamide, phenytoin, latanoprost, streptomycin, psoralen, minoxidil, cyclosporine, and diazoxide.
The responsibility of the endocrinopathies in the occurrence of hirsutism is rare, and the clinical picture is dominated by other more specific symptoms and signs:
Moderate hirsutism can be observed in pregnant women (physiological prolactin secretion) and postmenopausal women (relative hyperandrogenism due to the cessation of ovarian estrogen production).
Idiopathic hirsutism defines the hirsutism that occurs in association with regular menses, normal ovarian morphology, and normal plasmatic androgen levels. It is a diagnosis of exclusion after elimination of other etiologies. It represents about 10% of all cases of hirsutism and 50% of cases of mild hirsutism. It may be due to hypersensitivity of the pilosebaceous follicle receptors to androgens and peripheral conversation induced by the 5-reductase of testosterone to dihydrotestosterone ten-fold more active on the follicle-sebaceous unit. This has genetic determinism and is frequently reported in women of East Indian and Mediterranean origin.
The exact prevalence of hirsutism is not well known. It may be 10% or even higher than 50%. The psychological problem that this disease causes depends on ethnic and socio-cultural factors. Indeed, in some societies where the lack of hair is considered an important criterion of female beauty, a minimal hirsutism could be considered a severe disorder, while a much more pronounced hirsutism could be accepted in other societies.
Hirsutism is an androgen-dependent disorder resulting from the interaction between circulating androgen levels and the sensitivity of the hair follicle to androgens. The skin can retain testosterone in a more active androgen, dihydrotestosterone (DHT) through a 5alpha-reductase enzyme of which there are two isoenzymes, types 1 (chromosome 5) and 2 (chromosome 2), present in the skin and the hair follicle. In addition, the skin and the pilosebaceous follicle have an androgen receptor (AR).
After exclusion of an exogenous intake of androgens, hirsutism results either from hypersecretion of androgens, from the ovary or the adrenal gland, or from the increased cutaneous sensitivity of the skin to normal circulating levels of androgens. This last case is "idiopathic hirsutism."
The medical history is important. In case of hirsutism of peripubertal and slow onset, it indicates primary hirsutism or non-tumoral secondary hirsutism. A late onset or rapid progression, signs of virilization or high levels of hormones lead to adrenal (adenomas), ovarian (arrhenoblastoma) or pituitary (prolactinoma) tumors. Anamnesis of cycle disorders is an important indicator for secondary hirsutism (100% for tumors, 75% for polycystic ovaries, 0% to 25% for late adrenogenital syndrome).
The general characteristic is the sexual hair, whose density and properties change especially in the middle areas of the body. Most often, the face, chest, areolas, white line, buttocks, sacrum, inner thighs and external genitalia are affected. The severity of hirsutism can be quantified based on the Ferriman and Gallwey system, which evaluates nine areas of the body. For each, we assign points from 1 to 4 are assigned according to the density of hair, ranging from the absence of hair to severe hirsutism. One can then calculate a total score; if it is greater than 7, the maximum being 36, it is considered abnormal. Other common symptoms associated with excess androgens are acne, menstrual irregularities, the temporal recession of the hairline and frontal alopecia.
The basic biological assessment is performed in the early follicular phase (third to sixth day of the cycle, early morning, fasting) and after stopping a possible oral contraception for two or three cycles unless a tumor cause is suspected. It comprises total testosterone, dehydroepiandrosterone sulfate (DHEAS), delta4-androstenedione (delta4A), luteinizing hormone (LH) / follicle-stimulating hormone (FSH), 17-hydroxyprogesterone (17-OHP), steroid hormone-binding globulin (SHBG). In case of menstrual cycle disorder (amenorrhea, oligomenorrhea), the stimulating thyroid hormone (TSH) and prolactinemia (PRL) are included.
According to the clinical findings, One can add to the work up a short dexamethasone suppression test (Cushing syndrome), an adrenocorticotropic hormone (ACTH) stimulation test and a prolonged dexamethasone suppression test (late adrenogenital syndrome), a carbohydrate tolerance test or HOMA index (insulin resistance syndrome).
The diagnosis of idiopathic hirsutism is a diagnosis of exclusion. Approximately 15% to 50% of women suffering from hirsutism belong to this category. Its pathogenesis is then parallel to that of primary androgenetic alopecia.
Treatment of non-tumoral hirsutism still includes oral contraception. It inhibits by its progestogen the hypothalamic-pituitary axis, and thus the ovarian production of androgens; by its estrogen, it increases the SHBG. It is combined with an antiandrogenic treatment: flutamide, spironolactone, cyproterone acetate, finasteride are all used with variable but comparable results.
Adrenal hyperandrogenism is slowed down by low dose corticosteroids, possibly associated with the treatments as mentioned earlier.
Fine hair growth can be inhibited by twice, daily topical application of eflornithine. Electrolysis is less used now except for coarse white hairs and also in cases of polycystic ovaries without insulin resistance.
As the effect of drug treatment that occurs only after 1 to 2 years, clinicians use the cosmetic approaches that are also appropriate for hypertrichoses: shaving, hair removal, discoloration by hydrogen peroxide, chemical depilation (p. thioglycolates). Fine hair growth can be inhibited by twice-daily topical application of eflornithine. Electrolysis is not used as often as in the past, except in the case of coarse white hairs. It has been replaced by long-term depilation with tools like depilatory lasers and various intense pulsed light devices.
Surgical excision is necessary in case of the tumoral process. Ovariectomy may be indicated for severe hyperandrogenism in menopausal or perimenopausal women.
Hypertrichosis is a diffuse increase of hair forming down in areas not dependent on androgens (often the cheeks and arms). It may be the consequence of an excess of glucocorticoids, the taking of certain drugs (phenytoin, penicillamine, ciclosporin, minoxidil, diazoxide) and systemic disorders (anorexia nervosa, hypothyroidism, porphyria, dermatomyositis). Hypertrichosis is often due to a familial or ethnic character and has a prepubertal onset.
Lanugo is a very thin, villous, and non-pigmented hair located anywhere on the body. Hypertrichosis is characterized by an excessive growth of hair affecting normally hairy areas in women.
The diagnosis of hirsutism requires the careful collection of medical history data, physical examination, appropriate biological, and radiological investigations. Hirsutism can be idiopathic, which is a diagnosis of elimination, or secondary to hyperandrogenism that also encompasses other serious health problems including diabetes, metabolic syndromes, and infertility. In some cases, a tumor process is involved.
The management of hirsutism is multidisciplinary, including the dermatologist, the endocrinologist, and the gynecologist. The treatments used serve to reduce the severity of hirsutism, as well as to improve overall health and self-esteem.
|||Saleh D,Cook C, Hypertrichosis 2019 Jan; [PubMed PMID: 30521275]|
|||Kshetrimayum C,Sharma A,Mishra VV,Sunil K, Polycystic ovarian syndrome: Environmental/occupational, life style factors-an overview Journal of the Turkish German Gynecological Association. 2019 Mar 1; [PubMed PMID: 30821135]|
|||Gainder S,Sharma B, Update on Management of Polycystic Ovarian Syndrome for Dermatologists. Indian dermatology online journal. 2019 Mar-Apr; [PubMed PMID: 30984582]|
|||Toosy S,Sodi R,Pappachan JM, Lean polycystic ovary syndrome (PCOS): an evidence-based practical approach. Journal of diabetes and metabolic disorders. 2018 Dec; [PubMed PMID: 30918863]|
|||Jacobsen S,Lauszus FF, [Androgen-secreting tumours of the ovaries]. Ugeskrift for laeger. 2019 Feb 4; [PubMed PMID: 30729915]|
|||Zhou WB,Chen N,Li CJ, A rare case of pure testosterone-secreting adrenal adenoma in a postmenopausal elderly woman. BMC endocrine disorders. 2019 Jan 23; [PubMed PMID: 30674304]|
|||Shu S,Deng S,Tian JQ,Chen R,Sun JA,Yu Q,Zhu Liu F,Huang LR,Pan YL,Yang XJ,Fan BQ,Liu YH, The clinical features and reproductive prognosis of ovarian neoplasms with hyperandrogenemia: a retrospective analysis of 33 cases. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology. 2019 Apr 16; [PubMed PMID: 30990090]|
|||Zhang CD,Pichurin PN,Bobr A,Lyden ML,Young WF,Bancos I, Cushing syndrome: uncovering Carney complex due to novel PRKAR1A mutation. Endocrinology, diabetes [PubMed PMID: 30897549]|
|||Lumezi BG,Berisha VL,Pupovci HL,Goçi A,Hajrushi AB, Grading of hirsutism based on the Ferriman-Gallwey scoring system in Kosovar women. Postepy dermatologii i alergologii. 2018 Dec; [PubMed PMID: 30618534]|
|||Bienenfeld A,Azarchi S,Lo Sicco K,Marchbein S,Shapiro J,Nagler AR, Androgens in Women: Androgen mediated skin disease and patient evaluation (Part I). Journal of the American Academy of Dermatology. 2018 Oct 9; [PubMed PMID: 30312644]|
|||Hu AC,Chapman LW,Mesinkovska NA, The efficacy and use of finasteride in women: a systematic review. International journal of dermatology. 2019 Jan 3; [PubMed PMID: 30604525]|
|||Azarchi S,Bienenfeld A,Lo Sicco K,Marchbein S,Shapiro J,Nagler AR, Androgens in Women: Hormone modulating therapies for skin disease (Part II). Journal of the American Academy of Dermatology. 2018 Oct 9; [PubMed PMID: 30312645]|